Skip to main content

Drug Interactions between dinutuximab and Flebogamma

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

immune globulin intravenous dinutuximab

Applies to: Flebogamma (immune globulin intravenous) and dinutuximab

GENERALLY AVOID: Concomitant use of dinutuximab beta with intravenous immunoglobulin may lead to a reduction in the dose-dependent cytotoxic effects of dinutuximab beta. The mechanism has not been elucidated; however, it may relate to the effects of antibodies in immunoglobulin on the antibody dependent cell-mediated cellular cytotoxic effects of dinutuximab beta. Clinical data are not available. The interaction may also occur with dinutuximab. Clinical data are not available for intravenous immunoglobulin or for immunoglobulins administered via the intramuscular or subcutaneous routes.

MANAGEMENT: The manufacturer of dinutuximab beta recommends that concomitant use with intravenous immunoglobulins should be avoided (UK). If concomitant use is required, close clinical and laboratory monitoring for treatment efficacy is recommended both during and after discontinuation of therapy.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer